Early access
Sign in
Taking people in United StatesPhase 1

Safety of a new medicine, NNC6989-0001, in healthy people with overweight or obesity

Tests how safe NNC6989-0001 is in healthy adults with overweight or obesity.

Key facts

Who runs it
Novo Nordisk A/S
Where
Lenexa, United StatesSee the site
Trial code
Registry title
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
Status
Recruiting
Phase
Phase 1
People taking part
132 people, planned
Started
24 Feb 2026
Expected to end
21 Jan 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NNC6989-0001
  • Placebo (NNC6989-0001)
Record updated
29 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-55 who are in good health but live with overweight or obesity, to test the safety of a new medicine, NNC6989-0001.

Age
18 to 55 years
Sex
Men and women who cannot have children
Disease stage
Body mass index (BMI) of 25.0 or more and 34.9 or less for Part A. BMI of 25.0 or more and 39.9 or less for Parts B and C.
Earlier treatment
People cannot join if they took any GLP-1 RA or a medicine with GLP-1 activity within 90 days before screening.

Main reasons for not taking part

  • Any condition the investigator thinks could put safety or following the trial at risk
  • Body weight change of 5 % or more, or dieting attempts, within 90 days before screening
  • Treatment with a GLP-1 RA or a medicine with GLP-1 activity within 90 days before screening
  • Use of prescription or non-prescription medicines within 14 days before screening, with a few exceptions

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Male or female of non-childbearing potential
  • Age 18-55 years (both inclusive) at the time of signing the informed consent
  • Body mass index (BMI) (at screening) ≥ 25.0 and ≤ 34.9 kg/m\^2 for Part A (SAD part) and BMI (at screening) ≥ 25.0 and ≤ 39.9 kg/m\^2 for Part B (MAD part) and Part C (meal timing and potentially meal composition)
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator

Who cannot take part

  • Any clinically significant body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening
  • Treatment with any GLP-1 RA or a medication with GLP-1 activity within 90 days before screening
  • Use of prescription or non-prescription medicinal products within 14 days before screening. This includes over the counter medicines such as laxatives, mineral oil, and fat-blocking supplements. Routine multivitamin/mineral supplements at labelled daily doses are permitted; other non-prescription supplements (e.g., high-dose vitamins, weight-loss supplements) are not permitted. Occasional use of over-the-counter acetaminophen or NSAIDs at their labelled doses for mild pain is permitted
  • Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • ICON Early Phase Services, LLCLenexa, United StatesContact: Novo NordiskTaking people

About the trial

What the trial wants to find out

This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.

The 2 groups in the trial

  • NNC6989-0001Treatment being tested

    Participants receive the investigational drug NNC6989-0001

  • PlaceboPlacebo, for comparison

    Participants receive placebo matched in appearance to the active drug.

    Treatment: Placebo (NNC6989-0001)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single and Multiple Ascending Doses of NNC6989-0001 in Healthy Participants With Overweight or Obesity
Plain-language title
Safety of a new medicine, NNC6989-0001, in healthy people with overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07437079, who can take part
Record updated
29 July 2026